Benserazide-induced diarrhea - A retrospective clinical study.

Area of Science:

• Pharmacology
• Gastroenterology
• Neurology

Background:

• Benserazide-induced diarrhea (BID) is a rare but significant side effect of L-3,4- dihydroxyphenylpyrazine (L-DOPA)/benserazide treatment.
• Lack of literature and treatment recommendations for BID can lead to misdiagnosis and ineffective treatments, or unnecessary discontinuation of L-DOPA medication.
• This study addresses the knowledge gap by proposing a treatment and investigating potential pharmacological explanations.

Purpose of the Study:

• To recommend an effective treatment for benserazide-induced diarrhea (BID).
• To explore potential pharmacological reasons for BID.
• To fill the existing literature and clinical guidance gaps regarding BID.

Main Methods:

• Retrospective analysis of 50 patient case files with BID.
• Identification of patterns and concomitant conditions/medications in patients experiencing BID.

Main Results:

• The most common co-occurring condition was hypertension, likely due to the patients' advanced age.
• Beta-blockers and acetylsalicylic acid were the most frequently used concomitant medications.
• No other distinct patterns were identified in this patient cohort.

Conclusions:

• Switching to L-DOPA/carbidopa is a highly effective treatment for BID, typically resulting in rapid remission.
• Plasma protein binding differences between benserazide and carbidopa are hypothesized as a potential explanation for differential tolerance.
• Further research is needed to definitively establish the role of plasma protein binding due to conflicting data.